Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
Get 40% Off
/Free Sign Up
 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

Eckert & Ziegler BEBIG SA (EZBG)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
Eckert & Ziegler historical data, for real-time data please try another search
16.300 0.000    0.00%
18/02 - Closed. Currency in EUR ( Disclaimer )
Type:  Equity
Market:  Belgium
ISIN:  BE0974300320 
  • Volume: 0
  • Bid/Ask: 16.300 / 16.600
  • Day's Range: 16.200 - 16.300
Eckert & Ziegler 16.300 0.000 0.00%

Eckert & Ziegler BEBIG SA Company Profile

 
Get an in-depth profile of Eckert & Ziegler BEBIG SA, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryHealthcare Equipment & Supplies
SectorHealthcare
Employees

-

Equity Type

ORD

As of February 18, 2019, Eckert & Ziegler BEBIG S.A. was acquired by Eckert & Ziegler Strahlen- und Medizintechnik AG. Eckert & Ziegler BEBIG S.A. through its subsidiaries, develops, manufactures, and sells radiation equipment and related products based on isotope technology. It offers IsoSeed for the treatment of prostate cancer; Mick TP/TPV Applicator System, a brachytherapy implantation technique that allows for seed placement adjustments during implant to adapt changes of prostate size and position; IsoCord, a seed chain that provides radiation protection; IsoStrand, a seed chain that consists of 10 IsoSeeds with 1.0 cm center-to-center spacing for protection against radiation; and needles for LDR brachytherapy. The company also offers IsoSeed I25.S17plus loose seeds for brain tumor treatment; SagiNova and MultiSource HDR (high dose rate) afterloader systems for the HDR brachytherapy applications; SagiPlan software for HDR treatment plans; and Cobalt-60 for various HDR brachytherapy treatments. In addition, it offers gynecological and rectal HDR applicators and accessories; CT/MR contour prostate template sets; tongue and mouth, and nasopharynx applicator sets; breast bridge sets; esophagus applicator and bronchus intraluminal sets; Harrison-Anderson-Mick applicators; and Valencia applicator sets. Further, the company provides products for the temporary brachytherapy of eye cancers, including Ru-106 eye applicators for the treatment of uveal melanoma and retinoblastoma; and I-125 ophthalmic seeds for use in COMS eye applicators to treat eye tumors, such as uveal melanomas and retinoblastomas, as well as offers radiotherapy accessories. It markets and sells its products to oncologists, radiologists, urologists, and medical physicists through a network of distributors and agents worldwide. The company was formerly known as International Brachytherapy s.a. and changed its name to Eckert & Ziegler BEBIG S.A. in June 2011. The company was founded in 1996 and is headquartered in Seneffe, Belgium.

Contact Information

Address Rue Jules Bordet Zone Industrielle C
Seneffe, 7180
Belgium
Phone 32 6 452 08 08
Fax 32 6 452 08 01
Web www.ezag.com/home
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

EZBG Comments

Write your thoughts about Eckert & Ziegler BEBIG SA
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email